On November 5, 2026 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, reported that data from two clinical trials of its first-in-class MHC Class II agonist, eftilagimod alfa ("efti"), will be presented in poster presentations at two international congresses in November and December 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, taking place 18–21 November 2026 in Seoul, South Korea, survival data will be presented from the investigator-initiated EFTISARC-NEO Phase II trial evaluating efti in combination with KEYTRUDA (pembrolizumab) and radiotherapy in the neoadjuvant treatment of patients with resectable soft tissue sarcoma.
At the ESMO (Free ESMO Whitepaper) Immuno-Oncology & Advanced Therapies Congress 2026, taking place 14–16 December 2026 in London, United Kingdom, final median overall survival results will be presented from Part B of the TACTI-003 Phase IIb trial evaluating efti in combination with KEYTRUDA in first-line recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients with a PD-L1 combined positive score (CPS) of less than 1.
CTOS 2026 Annual Meeting
Title Disease Free Survival (DFS) in Patients with Resectable Soft Tissue Sarcoma (STS) from Eftisarc-Neo Phase II Trial of Neoadjuvant Eftilagimod Alfa (Efti), Pembrolizumab and Radiotherapy (Rth)
Trial EFTISARC-NEO (investigator-initiated Phase II; NCT06128863)
Session category Poster Discussion (SESSION 6)
First Author Pawel Sobczuk, MD PhD; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Mazowieckie, Poland
Poster session 19 November 2026, 04:30 p.m. KST (19 November, 06:30 p.m. AEDT)
ESMO Immuno-Oncology & Advanced Therapies Congress 2026
Title Eftilagimod Alfa and Pembrolizumab in First-Line Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with PD-L1 CPS <1: Final Results from the TACTI-003 Study
Trial TACTI-003 Part B (Phase II; NCT04811027)
Session category Poster Display session
First Author Claus A. Kristensen, MD PhD, Copenhagen University Hospital, Copenhagen, Denmark
Poster session 14 December 2026, 17:30 GMT (15 December 2026, 4:30am AEDT)
Details of the presentations are set out below. The data will be made available on the Posters & Publications page of Immutep’s website following their presentation.
(Press release, Immutep, NOV 5, 2026, View Source [SID1234674370])